Topical Bevacizumab for Preventing Recurrent Pterygium
Topical Bevacizumab for Preventing Recurrent Pterygium
The purpose of this study is to determine whether bevacizumab eye drop is effective in the
 treatment of recurrent pterygium.
A pterygium is a degenerative and proliferative fibrovascular disorder of the ocular surface.
 Patients may be asymptomatic, irritation, decreased vision, diplopia or limit ocular
 movement. The mainstay treatment is surgical removal of the head, neck and body of the
 pterygium. However, if there is no adjunctive treatment, the recurrence is unacceptably high
 which is 63% in general. Various adjunctive measures are applied to prevent recurrence
 including use of mitomycin C, beta-irradiation and surgical methods such as conjunctival and
 amniotic membrane graft. However, each method has its advantages and disadvantages.

 The histologic finding of recurrent pterygium often has aggressive fibrovascular growth.
 Vascular endothelial growth factor(VEGF)has been detected in increased amounts in pterygium
 tissue, compared with normal conjunctiva and it is also correlated with post-operative
 recurrence. Bevacizumab, an Anti-VEGF, binds to VEGF and prevents the interaction of VEGF to
 its receptors on the surface of vascular endothelial cells. Administration of bevacizumab
 leads to inhibition of endothelial cell proliferation and new blood vessel formation. Even
 though there are reported the efficacy of topical bevacizumab in inhibiting the impending
 recurrent pterygium, there is no study for preventing recurrence after primary pterygium
 removal.

 We conduct a prospective, randomized, double-masked, controlled trial to evaluate the
 efficacy of topical bevacizumab 0.05% eye drops for preventing recurrence in primary
 pterygium.
Inclusion Criteria:

 -  Patients who are diagnosed with primary pterygium and plan for pterygium excision with
 bare sclera by single surgeon. (G.N.)

 -  Patients with pterygium who understand and can follow the study protocol.

 -  Patients of age more than 30 years

 Exclusion Criteria:

 -  Patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial
 wound healing.

 -  Patients who are pregnancy or lactation.

 -  Patients who have a history of allergy to bevacizumab.

 -  Patients who have a history of allergy to steroid eye drops